-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

Benzinga·10/01/2026 09:21:01
Diffusion vocale
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.